BiotechTube

Placebo + BIAP

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sepsis

Conditions

Sepsis, Bacterial Infections and Mycoses

Trial Timeline

May 1, 2008 → Dec 1, 2009

NCT ID
NCT00511186

About Placebo + BIAP

Placebo + BIAP is a phase 2 stage product being developed by AM-Pharma for Sepsis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00511186. Target conditions include Sepsis, Bacterial Infections and Mycoses.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00511186Phase 2Terminated

Competing Products

20 competing products in Sepsis

See all competitors
ProductCompanyStageHype Score
Alkaline Phosphatase + PlaceboAM-PharmaPhase 2
44
Drotrecogin alfa (activated)Eli LillyPhase 2
52
MeropenemPfizerApproved
84
ImipenemMerckApproved
85
CefiderocolShionogiPhase 1
33
eritoran tetrasodium + PlaceboEisaiPhase 3
77
E5564EisaiPhase 2
52
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin Alfa (activated)Eli LillyApproved
85
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
sPLA2 InhibitorEli LillyPhase 1/2
41
Drotrecogin alfa (activated)Eli LillyApproved
85
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
AZD9773 (CytoFab)AstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52

Other Products from AM-Pharma

Recombinant human alkaline phosphatasePhase 3
69
Ilofotase alfa + PlaceboPhase 2
44
Alkaline Phosphatase + PlaceboPhase 2
44
recAPPhase 2
44
bovine intestinal alkaline phosphatase (BIAP)Phase 2
44